Perspective Therapeutics, Inc. (CATX) Stock

NYSE American: CATXDevelops radiopharmaceutical therapeutics for the treatment of cancer, combining precision targeting with potent therapeutic effects.

Perspective Therapeutics stock price chart

CATX interactive chart →

CATX stock quote & key statistics

Perspective Therapeutics earnings per share

Income →

Earnings per share

Perspective Therapeutics revenue & net income

Income →

RevenueNet income

Perspective Therapeutics annual financials

Income statement →

Perspective Therapeutics, Inc. revenue, net income and EPS by fiscal year
Fiscal year	Revenue	Net income	EPS
FY2025	$884,000	-$103.1M	-$1.41
FY2024	$1.5M	-$79.3M	-$1.16
FY2023	$1.4M	-$46.5M	-$0.90
FY2023	$7.1M	-$14.7M	—
FY2022	$5.4M	-$10.8M	-$0.16

Fiscal year ending December 31. Source: company filings via EODHD.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., based in Seattle, Washington, specializes in developing precision-targeted alpha therapies (TAT) for treating cancer patients with metastatic disease across various tumor types. The company is dedicated to discovering, designing, and advancing its initial program candidates, including VMT-a-NET and VMT01, both currently undergoing Phase 1/2a clinical trials.

VMT-a-NET is aimed at patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors who have not previously received peptide-targeted radiopharmaceutical therapy. Concurrently, VMT01 is being assessed in Phase 1/2a trials as a potential second-line treatment for patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Perspective Therapeutics has also established a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab for patients with histologically confirmed melanoma and positive MC1R imaging scans. Founded in 1998 as Isoray, Inc., the company rebranded to Perspective Therapeutics, Inc. in February 2022, solidifying its commitment to advancing innovative oncology therapies.

Perspective Therapeutics stock FAQ

What is the Perspective Therapeutics stock ticker symbol?

Perspective Therapeutics, Inc. trades on the NYSE American under the ticker symbol CATX.

What sector and industry is Perspective Therapeutics in?

Perspective Therapeutics, Inc. is classified in the Healthcare sector, Medical Devices industry.

How many employees does Perspective Therapeutics have?

Perspective Therapeutics, Inc. has about 163 full-time employees.

What were Perspective Therapeutics's revenue and earnings last fiscal year?

Perspective Therapeutics reported revenue of $884,000 and net income of -$103.1M in fiscal 2025, with earnings per share of -$1.41. Revenue declined 39.2% from the prior year.

Is Perspective Therapeutics in the Russell 2000?

Yes. Perspective Therapeutics, Inc. (CATX) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Perspective Therapeutics go public?

Perspective Therapeutics stock began trading on November 10, 2005.